- Home
- LOGC vs CRGX Comparison
LOGC vs CRGX Comparison
Compare LOGC & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOGC
- CRGX
- Stock Information
- Founded
- LOGC 2010
- CRGX 2021
- Country
- LOGC United States
- CRGX United States
- Employees
- LOGC N/A
- CRGX N/A
- Industry
- LOGC Catalog/Specialty Distribution
- CRGX
- Sector
- LOGC Consumer Discretionary
- CRGX
- Exchange
- LOGC Nasdaq
- CRGX Nasdaq
- Market Cap
- LOGC 186.8M
- CRGX 180.4M
- IPO Year
- LOGC 2020
- CRGX 2023
- Fundamental
- Price
- LOGC $6.95
- CRGX $4.18
- Analyst Decision
- LOGC
- CRGX Hold
- Analyst Count
- LOGC 0
- CRGX 7
- Target Price
- LOGC N/A
- CRGX $4.67
- AVG Volume (30 Days)
- LOGC 366.4K
- CRGX 794.0K
- Earning Date
- LOGC 03-12-2025
- CRGX 03-12-2025
- Dividend Yield
- LOGC N/A
- CRGX N/A
- EPS Growth
- LOGC N/A
- CRGX N/A
- EPS
- LOGC N/A
- CRGX N/A
- Revenue
- LOGC $43,000,000.00
- CRGX N/A
- Revenue This Year
- LOGC $433.37
- CRGX $119.08
- Revenue Next Year
- LOGC N/A
- CRGX N/A
- P/E Ratio
- LOGC N/A
- CRGX N/A
- Revenue Growth
- LOGC N/A
- CRGX N/A
- 52 Week Low
- LOGC $4.69
- CRGX $3.00
- 52 Week High
- LOGC $9.34
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- LOGC 38.65
- CRGX 42.53
- Support Level
- LOGC $7.36
- CRGX $3.98
- Resistance Level
- LOGC $7.73
- CRGX $4.25
- Average True Range (ATR)
- LOGC 0.29
- CRGX 0.23
- MACD
- LOGC -0.05
- CRGX 0.18
- Stochastic Oscillator
- LOGC 27.78
- CRGX 51.32
About LOGC ContextLogic Inc.
ContextLogic Inc is an online shopping store. The store provides personalized products, clothing products, accessories, gaming products and equipment, cosmetics, plastic products, mobile covers, and other products. Geographically, it derives majority of its revenue from Europe and also has a presence in North America; South America, and other countries.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.